PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
Abstract
Most patients with prostate cancer treated with androgen receptor (AR) signaling inhibitors develop therapeutic resistance due to restoration of AR functionality. Thus, there is a critical need for novel treatment approaches. Here we investigate the theranostic potential of hu5A10, a humanized mAb specifically targeting free PSA (KLK3).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 13, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-3614
Entities
People
- Christian Von Bodman
- Claire M. Storey
- Daniel L J Thorek
- Darren Veach
- David Ulmert
- Dmitry Pankov
- Hans Lilja
- Howard I. Scher
- Joanna Strand
- Katharina Braun
- Katharina Lueckerath
- Michael R. Mcdevitt
- Mohamed Altai
- Nadia Benabdallah
- Pat Zanzonico
- Peter Scardino
- Robert Damoiseaux
- Steven M. Larson
- Sven-erik Strand
- Teja Kalidindi
- Urpo Lamminmäki
Organizations
- Commonwealth Foundation
- Lund University
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- National Institutes of Health
- Prostate Cancer Foundation
- Ruhr University Bochum
- Swedish Cancer Society
- Swedish Research Council
- United States Department of Defense
- University of California
- University of California, Los Angeles
- University of Turku
- Washington University School of Medicine
- Weill Cornell Medicine